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Abstract
Backgrounds and Aims: Visceral fat has a crucial role in the development and progression of cardiovascular disease, the
major cause of death in end-stage renal disease (ESRD). Although sagittal abdominal diameter (SAD), as an index of visceral
fat, significantly correlated with mortality in the general population, the impact of SAD on clinical outcomes has never been
explored in ESRD patients. Therefore, we sought to elucidate the prognostic value of SAD in incident peritoneal dialysis (PD)
patients.
Methods: We prospectively determined SAD by lateral abdominal X-ray at PD initiation, and evaluated the association of
SAD with all-cause and cardiovascular mortality in 418 incident PD patients.
Results: The mean SAD was 24.564.3 cm, and during a mean follow-up of 39.4 months, 97 patients (23.2%) died, and 49.4%
of them died due to cardiovascular disease. SAD was a significant independent predictor of all-cause [3rd versus 1st tertile,
HR (hazard ratio): 3.333, 95% CI (confidence interval): 1.514–7.388, P = 0.01; per 1 cm increase, HR: 1.071, 95% CI: 1.005–
1.141, P = 0.03] and cardiovascular mortality (3rd versus 1st tertile, HR: 8.021, 95% CI: 1.994–32.273, P = 0.01; per 1 cm
increase, HR: 1.106, 95% CI: 1.007–1.214, P = 0.03). Multivariate fractional polynomial analysis also showed that all-cause and
cardiovascular mortality risk increased steadily with higher SAD values. In addition, SAD provided higher predictive value for
all-cause (AUC: 0.691 vs. 0.547, P,0.001) and cardiovascular mortality (AUC: 0.644 vs. 0.483, P,0.001) than body mass index
(BMI). Subgroup analysis revealed higher SAD ($24.2 cm) was significantly associated with all-cause mortality in men,
women, younger patients (,65 years), and patients with lower BMI (,22.3 kg/m2).
Conclusions: SAD determined by lateral abdominal X-ray at PD initiation was a significant independent predictor of all-
cause and cardiovascular mortality in incident PD patients. Estimating visceral fat by SAD could be useful to stratify mortality
risk in these patients.
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Introduction
Cardiovascular disease is the most common cause of death in
end-stage renal disease (ESRD) patients [1]. In addition to
advanced age, hypertension, diabetes, smoking, and dyslipidemia,
obesity has also been established as a risk factor for cardiovascular
morbidity and mortality in the general population [2–5]. Contrary
to the general population, some previous epidemiologic studies
have shown that high body mass index (BMI) is associated with
improved outcome in ESRD patients on hemodialysis (HD), which
is referred to as ‘‘reverse epidemiology’’ [6,7]. In patients with
peritoneal dialysis (PD), however, the association between BMI
and mortality has not been consistent [8–10]. Snyder et al [9]
demonstrated a significant survival advantage in PD patients with
high BMI, while a cohort study by McDonald et al [8] revealed
that obesity at PD initiation was an independent risk factor for
death and technique failure. Meanwhile, the United States Renal
Data System Dialysis Morbidity and Mortality Wave II Study
failed to find any survival advantage associated with high BMI in
PD patients [10].
To date, accumulating evidence has shown that central obesity
predicts clinical outcomes better than total obesity in the general
population and in patients with various diseases, including chronic
kidney disease (CKD) [11–17]. Waist-to-hip ratio (WHR) was
demonstrated to be a better predictor of cardiovascular risk than
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BMI in patients with moderate chronic kidney disease [13]. In
addition, waist circumference (WC) as well as WHR presented
stronger prognostic value for all-cause and cardiovascular mortal-
ity than BMI in ESRD patients [15]. On the other hand, among
the components of central obesity, visceral fat is more metabol-
ically active than subcutaneous fat, and a number of studies have
found that visceral fat is significantly associated with inflammation,
insulin resistance, and atherosclerosis [18–21]. Considering the
high mortality rates derived from cardiovascular disease in ESRD
patients and an insufficient power of WC, WHR, and abdominal
conicity index to discriminate between visceral and subcutaneous
fat, the exploration of a simple and reliable anthropometric index
representing visceral fat has clinical relevance in these patients.
Sagittal abdominal diameter (SAD), which measures the
anteroposterior diameter of the abdomen, significantly correlated
with visceral fat measured by computed tomography (CT),
magnetic resonance imaging (MRI), or dual-energy X-ray
absorptiometry in previous studies [22–25]. In addition, SAD
was a more powerful anthropometric index associated with cardio-
metabolic risk factors and insulin resistance than BMI, WC, and
WHR [26–28]. Furthermore, several large cohort studies have
demonstrated the prognostic value of SAD in the general
population [29–31]. However, the impact of SAD on clinical
outcome has never been explored in ESRD patients. Therefore,
we investigated whether SAD on lateral abdominal X-ray at PD
initiation was an independent predictor of mortality in incident PD
patients.
Methods
Ethics statement
The study was carried out in accordance with the Declaration of
Helsinki and approved by the Institutional Review Board of
Yonsei University Health System (YUHS) Clinical Trial Center.
We obtained informed written consent from all participants
involved in the present study.
Subjects
All consecutive ESRD patients over 18 years of age who started
PD at YUHS between January 2005 and July 2010 were initially
screened for enrollment in this prospective observational study.
Among a total of 533 incident PD patients, we excluded 21
patients who had history of malignancy (n = 14), active infection
(n = 4), or decompensated liver disease (n = 3) at the time of
enrollment. We also excluded 94 patients who discontinued PD
within the first 90 days after PD initiation due to following reasons:
loss to follow-up (n= 39), death (n = 37), transfer to HD (n= 12),
transplantation (n= 4), and recovery of kidney function (n = 2).
Therefore, remaining 418 patients were included in the final
analysis.
Clinical and Biochemical Data Collection
A well-trained examiner used a questionnaire to collect
demographic data. Traditional cardiovascular risk factors such
as age, hypertension, diabetes mellitus, smoking history, previous
history of cardiovascular disease, and PD modality were recorded.
Smoking status was classified as current, former, or never.
Cardiovascular disease was defined as a history of coronary,
cerebrovascular, or peripheral vascular disease: coronary disease
was defined as a history of angioplasty, coronary artery bypass
grafts, myocardial infarction, or angina and cerebrovascular
disease as a history of transient ischemic attack, stroke, or carotid
endarterectomy, while peripheral vascular disease was defined as a
history of claudication, ischemic limb loss and/or ulceration, or
peripheral revascularization procedure. BMI and biochemical
data were measured at the time of study enrollment. Patients were
weighed in light clothing, and height was measured with no shoes.
BMI was calculated as weight/height2 (kg/m2). Blood was taken
after a 12-hour overnight fast, and the following laboratory data
were measured: hemoglobin, blood urea nitrogen, creatinine,
albumin, triglyceride, total cholesterol, low-density lipoprotein
cholesterol, high-density lipoprotein cholesterol, calcium (Ca),
phosphorous (P), and intact parathyroid hormone (iPTH) concen-
trations. In addition, high-sensitivity C-reactive protein (hs-CRP)
levels were determined by a latex-enhanced immunonephelo-
metric method using a BNII analyzer (Dade Behring, Newark,
DE, USA). Residual renal function was estimated by a 24-hour
urine collection. To reflect the actual situation, usual overnight
dialysate volume and glucose concentrations were not changed for
this study. Kt/V urea was determined from the total loss of urea
nitrogen in spent dialysate using PD Adequest 2.0 for Windows
software (Baxter Healthcare, Deerfield, IL, USA).
Echocardiography
Echocardiography was performed on a day close to the time of
discharge based on the imaging protocol recommended by the
American Society of Echocardiography [32], to assess the cardiac
function of the patients. Left ventricular (LV) systolic function was
defined by LV ejection fraction using a modified biplane
Simpson’s method from the apical two-chamber and four-
chamber views.
Assessment of SAD by Lateral Abdominal X-ray
Lateral abdominal X-rays were taken in all subjects in a supine
position with the knee bent after dialysate were removed. SAD was
defined as the anterior-posterior distance, from skin to skin, at the
L4-L5 intervertebral disc level on a lateral abdominal X-ray. Two
trained medical doctors blinded to the patients’ clinical data
reviewed the X-rays and determined the SAD using an
electronical measure on a digital radiologic workstation (Centricity
Enterprise Web V3.0; GE Healthcare, Chalfont, UK). Any
discrepancies were resolved by an independent third observer.
Follow-up and Endpoints
Participants were followed up at intervals of 3 months through
October 31, 2011. All deaths and hospitalizations were recorded
in the serious adverse event database. Mortality events were
retrieved from the database and carefully reviewed to determine
all-cause and cardiovascular mortality. Cardiovascular mortality
was defined as death from myocardial infarction or ischemia,
congestive heart failure, pulmonary edema, cerebral infarction, or
peripheral vascular disease. When a patient died within 60 days
after transfer to HD, the death was regarded as a mortality event.
Loss to follow-up, renal transplantation, transfer to HD, or
recovery of renal function after the first 90 days of PD initiation
were censored at the end of PD treatment.
Statistical Analysis
Continuous variables were expressed as mean 6 SD, and
categorical variables were expressed as a number (percentage).
Since hs-CRP was not normally distributed, log-transformed
values were used. Subjects were divided into three groups
according to the SAD tertiles. To compare the baseline
characteristics according to the SAD tertiles, ANOVA and chi-
square tests were used for continuous variables and categorical
variables, respectively. Pearson’s correlation analysis was per-
formed to estimate the association between SAD and other
SAD as a Prognostic Factor in PD
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continuous variables. Cumulative survival curves were generated
by the Kaplan-Meier method, and between-group survival was
compared by a log-rank test. Independent prognostic values of
SAD for all-cause and cardiovascular mortality were ascertained
by Cox proportional hazards regression models, which included
traditional risk factors (age, sex, presence of diabetes and previous
cardiovascular disease, smoking status, systolic blood pressure, and
the use of lipid-lowering therapy), BMI, and biochemical data
associated with inflammation and nutrition in ESRD patients
(hemoglobin, albumin, Ca6P products, hs-CRP concentrations).
The prognostic value of SAD was also evaluated in a fractional
polynomial model. In addtion, the predictive values of SAD and
BMI for all-cause and cardiovascular mortality were compared
using receiver operating characteristic (ROC) curve analysis with
the calculated area under the ROC curve (AUC). Further
subgroup analysis was performed to elucidate the association of
SAD with mortality according to age, sex, and BMI. Age was
classified as two groups (,65 or $65 years), and SAD and BMI
were dichotomized by the median values (SAD, ,24.2 cm or
$24.2 cm; BMI, ,22.3 kg/m2 or $22.3 kg/m2). Statistical
analysis was performed using SPSS for Windows version 18.0
(SPSS Inc., Chicago, IL, USA) and STATA (version 11.0,
StataCorp, www.stata.com). A P value less than 0.05 was
considered statistically significant.
Results
Clinical Characteristics and Echocardiographic Findings
According to the SAD Tertiles
The baseline characteristics of the subjects according to the
SAD tertiles are shown in Table 1. The mean age was 55.9613.7
years (21–80 years), and 237 patients (56.6%) were male. Overall,
the mean SAD was 24.564.3 cm, and the mean SADs for each
tertile were 19.661.7, 24.461.2, and 29.561.9 cm. Diabetic
nephropathy was the most common cause of ESRD in all tertiels,
followed by chronic glomerulonephritis. The mean age, propor-
tion of males, proportion of patients with diabetes and previous
history of cardiovascular disease, and proportion of patients taking
lipid-lowering agents increased from the lowest to highest SAD
tertile. In addition, BMI and hs-CRP levels were significantly
higher, while albumin concentrations were significantly lower in
the highest SAD tertile group. On the other hand, there were no
significant differences in smoking status, PD modality, weekly Kt/
V urea, residual renal function, systolic blood pressure, hemoglo-
bin, serum glucose, creatinine, the ratio of total cholesterol to high-
density lipoprotein cholesterol, Ca6P products, the use of
antihypertensive drugs and phosphate binders, and LV ejection
fraction among the three groups.
Association of SAD with Clinical and Biochemical
Parameters
In the whole subjects, SAD was positively correlated with age
(r=0.35, P,0.001), BMI (r=0.64, P,0.001), and serum hs-CRP
concentrations (r=0.28, P,0.001), whereas there was an inverse
correlation between SAD and serum albumin levels (r=20.14,
P,0.001). Even when males and females were analyzed separate-
ly, the associations of SAD with age, BMI, and serum albumin and
hs-CRP concentrations remained significant (Table 2).
SAD as an Independent Risk Factor for All-cause and
Cardiovascular Mortality
During a mean follow-up duration of 39.4621.3 months, 97
patients (23.2%) died, and 49.4% of them died due to
cardiovascular disease. All-cause and cardiovascular mortality
rates were significantly and substantially increased with increasing
SAD tertiles. In the highest SAD tertile, all-cause and cardiovas-
cular death rates were 14.5 and 7.1 per 100 Person-Years,
respectively, which were significantly higher than those of the
lowest (2.5 and 0.7 per 100 Person-Years, respectively, P,0.001)
and middle SAD tertile (8.5 and 4.9 per 100 Person-Years,
respectively, P,0.001) (Table 3).
Kaplan-Meier analysis and Cox proportional hazard models
were performed to determine the prognostic value of SAD on
mortality. Both all-cause and cardiovascular mortality-free survival
rates decreased significantly and gradually as SAD tertiles were
increased (log-rank test, P,0.001) (Figure 1). In addition,
univariate Cox proportional hazard analysis revealed that older
age, the presence of diabetes and previous cardiovascular disease,
the use of lipid-lowering drugs, higher serum hs-CRP levels, and
lower serum albumin concentrations as well as higher SAD tertiles
were significant risk factors for all-cause and cardiovascular
mortality. In multivariate Cox analysis, the risks of all-cause and
cardiovascular death were increased with increasing SAD tertiles.
Relative to the lowest SAD tertile, the hazard ratios (HR) of all-
cause and cardiovascular mortality in the highest tertile were 3.333
and 8.021, respectively (Table 4). When included as a continuous
variable, SAD was a significant independent predictor of all-cause
(per 1 cm increase, HR: 1.071, 95% CI: 1.005–1.141, P=0.03)
and cardiovascular mortality (per 1 cm increase, HR: 1.106, 95%
CI: 1.007–1.214, P=0.03). In addition, when SAD was evaluated
in a fractional polynomial analysis, the risk of all-cause and
cardiovascular death increased steadily with higher SAD values
(Figure 2). Moreover, SAD provided higher predictive value for
all-cause (AUC: 0.691 vs. 0.547, P,0.001) and cardiovascular
mortality (AUC: 0.644 vs. 0.483, P,0.001) than BMI (Figure 3).
Prognostic Value of SAD for Mortality According to the
Sex, Age, and BMI Subgroups
The impact of SAD on mortality was further investigated
according to sex, age, and BMI subgroups (Figure 4). In men,
univariate Cox analysis revealed that older age, the presence of
diabetes mellitus and previous cardiovascular disease, smoking,
high BMI and serum hs-CRP levels, low serum albumin
concentrations, and higher SAD ($24.2 cm) were significant risk
factors for all-cause mortality. In multivariate Cox analysis, higher
SAD was a significant independent predictor of all-cause mortality
(HR: 1.986, 95% CI: 1.014–4.010, P=0.05). Subsequent
subgroup analysis showed that the risk of all-cause mortality for
the high SAD group was significantly higher in women (HR:
2.456, 95% CI: 1.074–5.617, P=0.03). In addition, higher SAD
was also significantly associated with all-cause mortality in the
young (,65 years, HR: 2.828, 95% CI: 1.210–6.608, P=0.01)
and low BMI group (,22.3 kg/m2, HR: 2.196, 95% CI: 1.109–
4.350, P=0.03). Meanwhile, higher SAD was significantly
associated with cardiovascular mortality only in women (HR:
6.017, 95% CI: 1.359–26.426, P=0.02) and the young age group
(HR: 2.269, 95% CI: 1.144–6.907, P=0.04).
Discussion
SAD is a simple and reliable anthropometric index representing
visceral fat, which is closely associated with cardiovascular disease
[18,20,21]. Since cardiovascular disease is the most common cause
of death in ESRD patients [1], it is surmised that there may be an
association between SAD and cardiovascular disease in these
patients, but this hypothesis has never been explored. In the
present study, we demonstrated for the first time that SAD on
SAD as a Prognostic Factor in PD
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Table 1. Baseline characteristics of the subjects according to the SAD tertiles.
Tertiles of SAD
(minimun-maximum,
cm)
Tertile 1 Tertile 2 Tertile 3
All (14.1–22.2) (22.3–26.9) (27.0–35.9)
Characteristics (n=418) (n=139) (n=139) (n=140) P
SAD (cm) 24.564.3 19.661.7 24.461.2 29.561.9 ,0.001
Age (years) 55.9613.7 49.6613.6 57.7613.2 60.2612.2 ,0.001
Male, n (%) 237 (56.6%) 62 (44.6%) 87 (62.5%) 88 (62.9%) ,0.001
Diabetes mellitus, n (%) 196 (46.8%) 47 (33.8%) 69 (49.6%) 80 (57.1%) ,0.001
Cardiovascular disease, n (%) 145 (34.6%) 30 (21.5%) 52 (37.4%) 63 (45.0%) ,0.001
Smoking status, n (%) 0.12
Current 7 (1.7%) 1 (0.7%) 3 (2.2%) 3 (2.1%)
Former 130 (31.1%) 33 (23.7%) 46 (33.1%) 51 (36.4%)
Never 281 (67.2%) 105 (75.5%) 90 (64.7%) 86 (61.4%)
Primary renal disease, n (%) 0.62
Diabetic nephropathy 170 (40.6%) 46 (33.0%) 62 (44.6%) 62 (44.2%)
Glomerulonephritis 114 (27.2%) 39 (28.0%) 37 (26.6%) 38 (27.1%)
Hypertensive nephrosclerosis 33 (7.8%) 12 (8.6%) 10 (7.1%) 11 (7.8%)
Polycystic kidney disease 5 (1.1%) 2 (1.4%) 2 (1.4%) 1 (0.7%)
Others/Unknown 96 (22.9%) 40 (28.7%) 28 (20.1%) 28 (20.0%)
PD modality, n (%) 0.79
CAPD 385 (92.1%) 129 (92.8%) 127 (91.4%) 129 (92.1%)
APD 33 (7.9%) 10 (7.2%) 12 (8.6%) 11 (7.9%)
Kt/V urea (per week) 2.260.6 2.160.5 2.260.6 2.360.6 0.16
RRF (mL/min/1.73 m2) 6.663.6 6.564.1 6.963.2 6.363.7 0.29
Systolic blood pressure (mmHg) 139.8620.3 139.6619.8 140.0620.3 139.7620.8 0.9
BMI (kg/m2) 22.663.1 20.462.0 22.462.2 25.163.1 ,0.001
Hemoglobin (g/L) 92615 93615 91615 91615 0.36
Glucose (mmol/L) 6.462.9 6.262.5 6.663.3 6.562.8 0.45
Blood urea nitrogen (mmol/L) 2.461.0 2.661.0 2.560.9 2.461.0 0.59
Creatinine (mmol/L) 6816274 6546265 6636274 6196274 0.07
Albumin (g/L) 3566 3666 3566 3465 0.01
Triglyceride (mmol/L) 1.360.6 1.360.5 1.260.6 1.360.6 0.38
Total cholesterol (mmol/L) 3.861.1 4.161.1 4.061.2 3.961.0 0.41
LDL-C (mmol/L) 2.761.2 3.061.7 2.561.0 2.561.1 0.28
HDL-C (mmol/L) 0.960.2 1.060.2 0.960.1 0.860.2 0.67
Total-to-HDL-C ratio 4.762.0 5.063.0 4.361.7 4.861.0 0.78
Ca6P product (mmoL2/L2) 3.461.0 3.461.0 3.560.9 3.461.0 0.61
iPTH (ng/L) 195.76168.3 207.56159.2 176.16166.4 203.76179.6 0.32
Log hs-CRP (mg/L) 20.160.8 20.360.9 20.160.8 0.160.7 ,0.001
Lipid-lowering agents, n (%) 145 (34.6%) 38 (27.3%) 50 (36.0%) 57 (40.7%) 0.01
Antihypertensive drugs, n (%)
RAS blockers 320 (76.5%) 104 (74.8%) 106 (76.2%) 110 (78.5%) 0.34
Beta-blockers 216 (51.6%) 68 (48.9%) 69 (49.6%) 79 (56.4%) 0.11
Calcium channel blockers 257 (61.4%) 83 (59.7%) 84 (60.4%) 90 (64.3%) 0.64
Phosphate binders, n (%) 0.81
Calcium-based 215 (51.4%) 71 (51.0%) 70 (50.3%) 74 (52.8%)
SAD as a Prognostic Factor in PD
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lateral abdominal X-ray at the start of PD was a significant
independent predictor of all-cause and cardiovascular mortality in
incident PD patients. In addition, the prognostic value of SAD was
stronger than BMI in these patients.
The impact of obesity, which was defined by BMI, on all-cause
and cardiovascular death has been widely investigated in the
general population [3,5]. However, several studies have revealed
that BMI in overweight and mildly obese individuals was
associated with lower mortality rates and fewer cardiovascular
events, a phenomenon called the ‘obesity paradox’ [33,34]. Even
though the reason for obesity paradox has not been completely
explained, several studies have suggested that it is attributed to
overadjustment for confounders, lack of statistical power, and
limitations of BMI to diagnose obesity [33,35,36]. In addition, it is
well known that BMI cannot differentiate fat and lean mass and
that BMI is affected by not only fat and muscle mass but also fluid
status [33]. Based on these findings, the need for new surrogates to
diagnose and provide better predictive value for all-cause and
cardiovascular mortality has emerged.
Visceral or central obesity has been supposed to have a greater
impact on cardiovascular events and mortality than total obesity,
as demonstrated by numerous studies on healthy subjects and
ESRD patients [11–17,21]. Postorino et al [15] found that WC,
but not BMI, was a significant independent predictor of all-cause
and cardiovascular mortality in 537 ESRD patients. In prevalent
PD patients, WHR also independently predicted mortality and the
first cardiovascular event [16]. Consistent with most previous
studies, we also showed that SAD, an index of central obesity, was
a significant independent predictor of all-cause and cardiovascular
mortality in incident PD patients, even after adjusting for BMI and
that SAD provided higher predictive value for mortality than
BMI. Moreover, our results revealed that SAD was significantly
associated with serum hs-CRP concentrations. Furthermore,
previous studies demonstrated that SAD had stronger correlations
to cardio-metabolic risk factors than BMI [26–28,37,38]. Similar-
ly, a study by Kalantar-Zadeh et al [39] found that the
concentrations of inflammatory markers were comparable among
the four different BMI groups of ESRD patients. SAD has also
been known to be associated with insulin resistance
[28,37,38,40,41]. Pouliot et al [41] showed that SAD was
significantly associated with fasting glucose and postglucose insulin
levels in 151 healthy subjects. In addition, SAD was also a
significant predictor of insulins resistance in moderately obese men
[37] and severely obese patients [28]. Moreover, SAD explained a
greater portion of variation of insulin resistance and CRP levels in
immigrant women from the Middle East and native Swedish
women [38], and Chinese hypertensive patients [40]. Based on
these findings, we speculated that a close relationship among
visceral fat, cardio-metabolic risk, inflammation, insulin resistance,
and SAD might contribute to the deleterious effect of SAD on
mortality. On the other hand, higher SAD was significantly
associated with all-cause mortality in the lower BMI group, but not
the higher BMI group. Since the interaction between SAD and
BMI was significantly stronger in the higher BMI group, we infer
that the impact of SAD on mortality may be lessened in the higher
BMI group.
Table 2. Pearson’s correlation test for the association of SAD
with clinical and biochemical variables.
Characteristics All Men Women
(n=481) (n=241) (n=177)
Age 0.35* 0.31* 0.41*
Kt/V urea (per week) 0.14 0.13 0.15
Systolic blood pressure 20.02 0.01 0.09
BMI 0.64* 0.59* 0.68*
Hemoglobin 20.06 20.06 20.08
Glucose 0.08 0.07 0.08
Blood urea nitrogen 20.07 20.01 0.16
Creatinine 20.21 20.17 20.31
Albumin 20.14* 20.16* 20.10*
Total cholesterol 20.06 20.09 0.02
LDL-C (mmol/L) 20.11 20.29 0.01
HDL-C (mmol/L) 20.13 20.15 20.11
Total-to-HDL-C ratio 0.11 0.15 0.10
Ca6P product 20.05 0.11 0.01
iPTH 20.01 20.01 0.01
Log hs-CRP 0.28* 0.32* 0.25*
Abbreviations: SAD, sagittal abdominal diameter; Kt/V, fractional urea clearance;
BMI, body mass index; LDL-C, low-density lipoproein cholesterol; HDL-C, high-
density lipoprotein cholesterol; Ca, calcium; P, phosphorous; iPTH, intact
parathyroid hormone; hs-CRP, high-sensitivity C-reactive protein.
*P,0.001.
doi:10.1371/journal.pone.0077082.t002
Table 1. Cont.
Tertiles of SAD
(minimun-maximum,
cm)
Tertile 1 Tertile 2 Tertile 3
All (14.1–22.2) (22.3–26.9) (27.0–35.9)
Characteristics (n=418) (n=139) (n=139) (n=140) P
Non calcium-based 32 (7.6%) 10 (7.1%) 10 (7.1%) 12 (8.5%)
LV ejection fraction (%) 56.0613.6 53.8611.3 56.5611.6 56.7617.4 0.81
Note: Data are expressed as mean 6 standard deviation or number of patients (percent).
Abbreviations: SAD, sagittal abdominal diameter; PD, peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; APD, automated peritoneal dialysis; Kt/V,
fractional urea clearance; RRF, residual renal function; BMI, body mass index; LDL-C, low-density lipoproein cholesterol; HDL-C, high-density lipoprotein cholesterol; Ca,
calcium; P, phosphorous; iPTH, intact parathyroid hormone; hs-CRP, high-sensitivity C-reactive protein; RAS, Renin-angiotensin system; LV, left ventricular.
doi:10.1371/journal.pone.0077082.t001
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SAD is the anteroposterior diameter of the abdomen, or
‘abdominal height’, and has been demonstrated to be closely
related to visceral fat in previous studies [22–25]. Kvist et al [22]
showed that SAD was a significant predictor of visceral fat volume
determined by CT in 27 healthy subjects, indicating that SAD was
useful in evaluating visceral obesity. The changes in SAD also
correlated with the loss of visceral fat area on MRI in obese
patients [23]. Furthermore, SAD had a stronger predictive value
for identifying visceral fat than any other anthropometric indices
[24,25]. Similar to western subjects [22–24], SAD was revealed to
have a stronger correlation with visceral fat area on CT compared
to BMI, WC, and transverse abdominal diameter in 5,257 Korean
subjects [25]. Since subcutaneous fat is displaced inferiorly by
gravity in the supine position, SAD measured in the supine
position could better represent visceral fat [22]. For these reasons,
in the current study, we measured SAD by lateral abdominal X-
ray taken in the supine position and used it as an index of central
obesity. In addition, since the assessment was performed at fixed
point of the L4-5 level on X-rays, we presumed that the
intraobserver variability of SAD measurements by X-ray was less
than using a caliper. In this study, the mean SAD was 25.2 cm in
men, and 23.7 cm in women, which were higher than the Asian
general population. The results of a study of 282 Japanese men
and another study of 131 Chinese men revealed that the mean
values of SAD were 18.7 and 19.5 cm, respectively [40,42]. The
mean SAD in women of our study was also higher than Chinese
women (23.7 vs. 18.8 cm) [40]. Moreover, when patients were
classified by sex and age, the mean SADs of the current study were
higher than those of a study in 5,257 Korean general population
(,50 years men, 23.7 vs. 22.7 cm; $50 years men, 23.3 vs.
22.6 cm; ,50 years women, 21.0 vs. 18.5 cm; $50 years women,
25.0 vs. 20.0 cm) [25]. The reason why there is a disparity in SAD
between the subjects of the present study and the Asian general
population is not clear, but it is presumed that chronic
inflammation status, more comorbid diseases such as diabetes,
and low physical activity in incident ESRD patients may
contribute to this difference.
In this study, even though total cholesterol levels were tended to
have a negative correlation with SAD, total cholesterol concen-
trations were not different among the SAD tertiles. However, the
proportion of patients taking statin was significantly higher in
patients with higher SAD tertile. When we performed additional
correlation tests according to the use of lipid-lowering therapy,
SAD showed a significant positive association with total cholesterol
levels in non-user of statin (statin user, r=20.154, P=0.31; non-
user, r = 0.082, P= 0.011). Therefore, we surmised that these
Figure 1. Kaplan-Meier analysis of (A) all-cause and (B) cardiovascular mortality according to the SAD tertiles. Patients with higher
SAD tertiles showed significantly higher all-cause and cardiovascular mortality (both log-rank test, P,0.001). Abbreviations: SAD, sagittal abdominal
diameter.
doi:10.1371/journal.pone.0077082.g001
Table 3. All-cause and cardiovascular death rates according to the SAD tertiles.
Tertiles of SAD
(minimun-maximum, cm)
No. of events
/No. of patients
Follow-up,
No. of Person-Years
Event rate per
100 Person-Years
All-cause death
Tertile 1 (14.1–22.2) 11/139 434.5 2.5
Tertile 2 (22.3–26.9) 35/139 407.5 8.5
Tertile 3 (27.0–35.9) 51/140 350.4 14.5
Cardiovascular death
Tertile 1 (14.1–22.2) 3/139 434.5 0.7
Tertile 2 (22.3–26.9) 20/139 407.5 4.9
Tertile 3 (27.0–35.9) 25/140 350.4 7.1
Abbreviation: SAD, sagittal abdominal diameter.
doi:10.1371/journal.pone.0077082.t003
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discrepant data might be attributed to lipid-lowering therapy.
Meanwhile, the results of our study revealed that SAD was
negatively associated with serum albumin concentrations. Hypo-
albuminemia is a common complication in PD patients and the
causes of hypoalbuminemia are complex such as aging, malnutri-
tion, ultrafiltration failure, excess protein loss through the
peritoneal membrane, and systemic inflammation [43,44]. Since
there was a significant positive association between hs-CRP levels
and SAD, and hs-CRP levels were significantly higher in the
highest SAD group, we suggested that enhanced inflammation in
patients with higher SAD could be a possible reason of
hypoalbuminemia in the higher SAD groups. However, these
findings were the results of cross-sectional data analysis, the cause
and effect relationship could not be determined. Furthermore,
other data representing nutritional status, including measurement
of daily food intake balance, normalized protein catabolic rate, or
subjective global assessment were not available in the current
study. In this regard, the association between SAD and nutritional
status could not be completely elucidated in the present study.
The prognostic value of SAD has been investigated in only a few
previous studies [29–31]. The Baltimore Longitudinal Study on
Aging, which was a prospective study in 981 males at the National
Institute on Aging in Baltimore, found that SAD was a strong
predictor of all-cause and coronary heart disease mortality in
young adults [29]. In 7,079 asymptomatic men in the Paris
Prospective Study I, the risk of sudden death increased propor-
tionally with increasing SAD quintile [30]. In addition, another
cohort study on 101,765 subjects undergoing a health checkup
identified that standing SAD was a strong predictor of coronary
heart disease independently of BMI [31]. To date, however, the
association of SAD with the clinical outcome has never been
elucidated in ESRD patients. In this study, we show for the first
time that SAD at PD initiation is a significant independent
predictor of all-caue and cardiovascular mortality in ESRD
patients. Moreover, while the majority of subjects were male in
previous studies that demonstrated a good predictive value of SAD
for the clinical outcome [29,30], our study revealed that higher
SAD was a significant independent predictor of mortality in both
men and women. On the other hand, a significant association
between higher SAD and mortality was observed in the younger
age and lower BMI groups but not in the older age and higher
BMI groups. The exact reason for this different impact of SAD is
not clear, but it may be attributed to the possibility that SAD may
Figure 2. Multivariate fractional polynomial graphs for the association between SAD and (A) all-cause mortality and (B)
cardiovascular mortality. Hazard ratios were calculated after adjustment for age, sex, diabetes mellitus, previous history of cardiovascular disease,
smoking status, systolic blood pressure, the use of lipid-lowering therapy, BMI, and biochemical data (hemoglobin, albumin, Ca6P products, and log
hs-CRP levels). Shaded areas indicate the 95% confidence limits. Abbreviations: SAD, sagittal abdominal diameter; BMI, body mass index; Ca, calcium;
P, phosphorous; hs-CRP, high-sensitivity C-reactive protein.
doi:10.1371/journal.pone.0077082.g002
Table 4. Cox’s proportional hazard models of SAD for all-cause and cardiovascular mortality.
Crude Model 11 Model 22
HR (95% CI) P HR (95% CI) P HR (95% CI) P
All-cause mortality
SAD (per 1 cm) 1.143 (1.092–1.198) ,0.001 1.090 (1.022–1.163) 0.01 1.071 (1.005–1.141) 0.03
Tertile 1 (14.1–22.2) 1 (reference) 1 (reference) 1 (reference)
Tertile 2 (22.3–26.9) 3.413 (1.733–6.721) ,0.001 1.975 (0.934–4.175) 0.07 2.366 (1.116–5.015) 0.03
Tertile 3 (27.0–35.9) 5.820 (3.028–11.188) ,0.001 3.538 (1.590–7.872) 0.01 3.333 (1.514–7.338) 0.01
Cardiovascular mortality
SAD (per 1 cm) 1.160 (1.085–1.239) ,0.001 1.130 (1.030–1.240) 0.01 1.106 (1.007–1.214) 0.03
Tertile 1 (14.1–22.2) 1 (reference) 1 (reference) 1 (reference)
Tertile 2 (22.3–26.9) 7.226 (2.146–24.323) ,0.001 5.535 (1.494–20.504) 0.01 5.955 (1.603–22.114) 0.01
Tertile 3 (27.0–35.9) 10.660 (3.221–35.385) ,0.001 10.690 (2.662–42.931) 0.01 8.021 (1.994–32.273) 0.01
Abbreviations: SAD, sagittal abdominal diameter; HR, hazard ratio; CI, confidence interval; BMI, body mass index.
1Model 1: adjusted for age, sex, diabetes mellitus, previous history of cardiovascular disease, smoking, systolic blood pressure, and lipid-lowering agents, and BMI.
2Model 2: Model 1+ biochemical data (hemoglobin, albumin, calcium6phosphorus products, and log high-sensitivity C-reactive protein levels).
doi:10.1371/journal.pone.0077082.t004
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exert more deleterious effect in patients with low risk of mortality
compared to patients with high mortality risk.
The current study has several limitations. First, although
previous studies found a significant association between SAD
and visceral fat [22–25], CT and MRI were not performed to
estimate visceral fat due to costs and radiation exposure. Second,
other anthropometric indices, such as WHR and WC, were not
evaluated, and the predictability of these indices for the clinical
outcome was not compared with that of SAD. Third, patients on
HD were not included. Since HD patients are generally followed
up at private clinics but not at our institute, it was not easy to
determine their final outcome. Finally, since SAD was determined
only at the start of PD, the effect of changes in SAD during follow-
up was not evaluated. Despite these limitations, we believe that
this prospective observational study provides useful information on
the effect of SAD on the clinical outcome in incident PD patients.
In conclusion, the present study demonstrates for the first time
that SAD on lateral abdominal X-ray at PD commencement was a
Figure 4. HRs of all-cause mortality for higher SAD ($24.2 cm) in different subgroups of 418 patients. Higher SAD was significantly
associated with increased risk of all-cause mortality in men, women, younger age (,65 years), and lower BMI groups (,22.3 kg/m2). Adjusted HRs
were calculated after adjustment for age, sex, diabetes mellitus, previous history of cardiovascular disease, smoking, systolic blood pressure, the use
of lipid-lowering therapy, BMI, and biochemical data (hemoglobin, albumin, Ca6P products, and log hs-CRP levels). Abbreviations: SAD, sagittal
abdominal diameter; BMI, body mass index; Ca, calcium; P, phosphorous; hs-CRP, high-sensitivity C-reactive protein; HR, hazard ratio; CI, confidence
interval.
doi:10.1371/journal.pone.0077082.g004
Figure 3. Receiver operating characteristic (ROC) curve for SAD and BMI to predict (A) all-cause and (B) cardiovascular mortality.
SAD provided higher predictive accuracy for all-cause and cardiovascular mortality than BMI (both P,0.001). Abbreviations: SAD, sagittal abdominal
diameter; BMI, body mass index; AUC, area under the ROC curve.
doi:10.1371/journal.pone.0077082.g003
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significant independent predictor for all-cause and cardiovascular
mortality in incident PD patients. Considering the significant
association of visceral fat with inflammation and cardiovascular
risk, estimating visceral fat by SAD on lateral abdominal X-ray
could be a useful tool to stratify mortality risk in these patients.
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